Skip to main content

Table 3 Novel therapeutics suitable for repositioning for the seven diseases

From: Identification of novel therapeutics for complex diseases from genome-wide association data

PH Target *Drug name Status Current Indication Action *Database
T1D RARA Alitretinoin Approved Kaposi's sarcoma Agonist TTD
  GSK3B Lithium Unknown Bipolar disorder Unknown PharmGKB
T2D CHRM1 Pirenzepine Approved Peptic ulcer disease Antagonist TTD
  LPL Gemfibrozil Approved Hyperlipidemia Activator TTD
CAD FLT1 Sorafenib Launched Advanced renal cell carcinoma Inhibitor TTD
  KDR Sunitinib Launched Advanced renal cell carcinoma Inhibitor TTD
BD ESR1 Trilostane Approved Cushing's syndrome aModulator DrugBank
  ABCC1 Methotrexate Unknown Psoriasis Unknown PharmGKB
HT TACR1 GSK1144814 Phase I Schizophrenia Antagonist TTD
  NRP1 Palifermin Approved Oral mucositis Unknown DrugBank
CD CRHR1 CRF-1 antagonist Phase II completed Irritable bowel syndrome Antagonist TTD
  INSR Insulin Detemir Approved Type I and II Diabetes Agonist DrugBank
RA HLA - DRB 1 Glatiramer Acetate Approved Multiple sclerosis Binder TTD
  ACE Ramipril Approved Hypertension Inhibitor DrugBank
  1. Abbreviations - PH - Phenotypes; T2D - Type 2 Diabetes; T1D - Type 1 Diabetes; CAD - Coronary Artery Disease; BD - Bipolar Disorder; HT - Hypertension; CD - Crohn's Disease; RA - Rheumatoid Arthritis; TTD - Therapeutic Target Database; PharmGKB - Pharmacogenomics Knowledgebase.
  2. Examples of novel therapeutics suitable for repositioning towards cure of seven diseases. (* Drugs mentioned in the table are only examples as one target may have multiple drugs); (* Drug databases in the table are only examples as one drug-target association may be present in more than one database); (a Allosteric Modulator).